Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Clinical Trial of KTP-001 in Lumbar Disc Herniation
jRCT2031210516Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant human matrix metalloproteinase in Herniated Lumbar Disk, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety and tolerability of KTP-001. Started Jan 2022; status: active, not recruiting.
02
Drugs
recombinant human matrix metalloproteinase
03
Conditions
Herniated Lumbar Disk
Beyond the preview
Go deeper on jRCT2031210516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210516.